|
Drug-Diagnostic Sponsors Must Educate Sites to Avoid Bias That Can Kill Approval
Sponsors of new drugs seeking approval with a companion in vitro diagnostic (IVD) need to work with trial sites to ensure they are not prescreening patients by local test methods — a process that can prove fatal for regulatory approval, an expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives